As of November 10, 2026, Azora Therapeutics, Inc. has Schedule 13D or 13G filings on record, none whose latest reports a stake of 5% or more. 5 filings are on record since February 18, 2026 (Schedule 13G/A, November 3, 2026).
Sell to companies like Azora Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Coastlands Capital LP · Sole voting: 0 · Shared voting: 655,975 · Sole dispositive: 0 · Shared dispositive: 655,975 · SCHEDULE 13G/A, 2026-11-03
- · Holder: Coastlands Capital LP · Percent: 14.22% · SCHEDULE 13G/A
- · Holder: Coastlands Capital LP · Percent: 9.98% · SCHEDULE 13G
- · Reporting person: Armistice Capital, LLC · Sole voting: 0 · Shared voting: 274,139 · Sole dispositive: 0 · Shared dispositive: 274,139 · SCHEDULE 13G/A, 2026-05-15
- · Holder: Armistice Capital, LLC · Percent: 9.99% · SCHEDULE 13G
Azora Therapeutics, Inc. has 5 Schedule 13D or 13G filings on record since 2026-02-18. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Armistice Capital, LLC | 4.99% | 274,139 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Coastlands Capital LP | 4.99% | 655,975 | SCHEDULE 13G/A, 2026-11-03 | 2026-11-02 |
Holding shares or following this stake? See who's behind Azora Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Azora Therapeutics, Inc. and the records around it.
Azora Therapeutics, Inc. elsewhere on the record
- Leadership changes Nov 2026
- Acquisition Jun 2026
- Form D filing Dec 2025
- Form D filing May 2025
- Who owns it
Companies that share a holder
- Coastlands Capital LP also filed stake reports on 15 other companies: Bolt Biotherapeutics, Inc. (Nov 2026), Kalaris Therapeutics, Inc. (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Azora Therapeutics, Inc.
Get an email when Azora Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Azora Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Azora Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Azora Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 0 | 274,139 | 0 | 274,139 | SCHEDULE 13G/A, 2026-05-15 |
| Steven Boyd | 0 | 274,139 | 0 | 274,139 | SCHEDULE 13G/A, 2026-05-15 |
| Coastlands Capital LP | 0 | 655,975 | 0 | 655,975 | SCHEDULE 13G/A, 2026-11-03 |
| Coastlands Capital Partners LP | 0 | 655,975 | 0 | 655,975 | SCHEDULE 13G/A, 2026-11-03 |
| Coastlands Capital GP LLC | 0 | 655,975 | 0 | 655,975 | SCHEDULE 13G/A, 2026-11-03 |
| Coastlands Capital LLC | 0 | 655,975 | 0 | 655,975 | SCHEDULE 13G/A, 2026-11-03 |
| Matthew D. Perry | 0 | 655,975 | 0 | 655,975 | SCHEDULE 13G/A, 2026-11-03 |
The latest filing identifies Azora Therapeutics, Inc. by CUSIP 054800107 and gives its principal executive office as 4267 VALLEY MEADOW ROAD, ENCINO, CA 91436 (SCHEDULE 13G/A, 2026-11-03).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-02-18 | Armistice Capital, LLC | 9.99% | SCHEDULE 13G |
| 2026-05-15 | Armistice Capital, LLC | 4.99% | SCHEDULE 13G/A |
| 2026-06-24 | Coastlands Capital LP | 9.98% | SCHEDULE 13G |
| 2026-07-01 | Coastlands Capital LP | 14.22% | SCHEDULE 13G/A |
| 2026-11-03 | Coastlands Capital LP | 4.99% | SCHEDULE 13G/A |
Also on the record for Azora Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 9, 2026 | Leadership change: Aida Habtezion appointed, Director | — | Leadership changes | Source |
| October 28, 2026 | Leadership change: Matthew Davidson appointed, President and Chief Executive Officer, and 2 more | — | Leadership changes | Source |
| August 13, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| June 11, 2026 | Acquired Azora Therapeutics, Inc. | $26.80M | Acquisition | Source |
| June 11, 2026 | Leadership change: Tony Goodman departs, and 1 more | — | Leadership changes | Source |
| December 3, 2025 | Form D, private offering | $4.29M sold | Form D page | Source |
| May 14, 2025 | Form D, private offering | $4.82M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Azora Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.